Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AERx inhaled human insulin versus metformin + glimepiride in type 2 diabetes
2006-004623-12Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Feb 2007
- Modality
- Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of regular human insulin, metformin and glimepiride in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Novo Nordisk. Primary endpoint: Change in HbA1c from baseline after 18 weeks of treatment. Started Feb 2007; status: completed.
02
Drugs
regular human insulinmetforminglimepiride
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2006-004623-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-004623-12.